CORRECTION article
Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
This article is part of the Research TopicEvolution of Antimicrobial Resistance GenesView all 4 articles
Correction: Molecular resistance mechanisms to newly approved antibiotics (2017–2025) in WHO priority pathogens
Provisionally accepted
- Frontiers Media SA, Lausanne, Switzerland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
A Correction on: Sartori M, Toppo S and Lavezzo E (2026) Molecular resistance mechanisms to newly approved antibiotics (2017)(2018)(2019)(2020)(2021)(2022)(2023)(2024)(2025) in WHO priority pathogens. Front. Microbiol. 16:1719798. doi: 10.3389/fmicb.2025.1719798 The hierarchical structure of sections and sub-sections were incorrectly formatted in the final version of the article.• The bullet points starting at "In E. coli, expression of the AmpC…" are intended as sub-sections of "Enzymatic inactivation", page 4, Aztreonam-avibactam.• The sections starting at "Alterations in iron transport systems." are intended as sub-sections of "Resistance mechanisms", page 5, Cefiderocol.• The sections starting at "A. baumannii:" are sub-subsections of the section "Alterations in iron transport systems", page 6, Cefiderocol.• Similarly, the sections starting at "Reduced outer membrane permeability." are sub-sections of "Resistance mechanisms", page 7, Meropenem-vaborbactam.• The sections at "OmpK35 inactivation:" are sub-sections of the "K. pneumoniae" , page 7, Meropenem-vaborbactam.• Sections beginning at lines "Mutations in ddn" are sub-sections of "Resistance mechanisms", page 8, Pretomanid.• Sections beginning at "Increased efflux pump expression" are sub-sections of "Resistance mechanisms", page 8, Lefamulin.• Sections beginning at lines "Efflux pump overexpression" are sub-sections of "Resistance mechanisms", page 9, Omadacycline.Last Name author1 et al.Frontiers Media SA PAGE \* Arabic \* MERGEFORMAT 3• Sections beginning at lines "Efflux pump overexpression" are sub-sections of "Resistance mechanisms", page 9, Eravacycline.• Sections beginning at "Modification of target sites" are sub-sections of "Resistance mechanisms", page 10, Plazomicin.• Sections beginning at "Enzymatic inactivation" are sub-sections of "Resistance mechanisms", page 11, Rifamycin SV.• Sections beginning at "Target site modifications" are sub-sections of "General resistance mechanisms", page 12, Quinolones and fluoroquinolones.• Sections beginning at "Increased efflux pump expression" are sub-sections of "Resistance mechanisms", page 12, Delafloxacin.The original version of this article has been updated.
Keywords: Antimicrobial resistance (AMR), Molecular diagnostics, Novel antibiotics, resistance mechanisms, WHO priority pathogens
Received: 22 Jan 2026; Accepted: 22 Jan 2026.
Copyright: © 2026 Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Frontiers Production Office
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.